Observations on the physostigmine syndrome in patients with Alzheimer's disease
Abstract
The authors present two patients with Alzheimer's disease who each received a single intravenous dose of physostigmine. Subjective complaints and mood changes were disproportional with objectively verified physiological side effects. Such observations may contribute to an understanding of affective disorders and should receive more attention in future studies of cholinesterase inhibitors.
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.- Personal login
- Institutional Login
- Sign in via OpenAthens
- Register for access
-
Please login/register if you wish to pair your device and check access availability.
Not a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).